Larazotide Acetate vs Teduglutide
Both act on the intestine but in different ways: larazotide regulates tight junctions to reduce permeability, teduglutide is a GLP-2 analogue approved for short bowel syndrome that increases intestinal absorptive surface.
Larazotide Acetate
An 8-amino-acid tight-junction regulator designed to reduce intestinal permeability, studied mainly in coeliac disease.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
Teduglutide
A degradation-resistant analogue of glucagon-like peptide-2 (GLP-2), approved for short bowel syndrome.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
SIDE BY SIDE
| Larazotide Acetate | Teduglutide | |
|---|---|---|
| The key difference | Tightens gut barrier | Grows gut lining (GLP-2 analogue) |
| Class | Repair & immune | Repair & immune |
| Mechanism | Larazotide is proposed to antagonise zonulin-mediated opening of epithelial tight junctions, limiting paracellular passage of gliadin fragments in the gut. | GLP-2 is a gut hormone that promotes growth and maintenance of the intestinal lining. |
| Status | Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models. | Approved (EU/US) for short bowel syndrome in adults and children; real-world and paediatric evidence is accumulating. |
| Reported safety signals | Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme. | Because it is intestinotrophic, labelling and reviews discuss monitoring for polyp growth; the "double-edged sword" debate centres on this growth effect. |
| A key study | Reviews tight-junction regulation in coeliac disease with a focus on larazotide. (Ther Adv Gastroenterol 2016, PMID 26770266) | Reviews teduglutide as a GLP-2 analogue that increases intestinal absorption in short bowel syndrome. (Drugs 2017, PMID 28194723) |
WHEN TO RESEARCH WHICH
Larazotide for barrier function; teduglutide for intestinal growth and absorption. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Larazotide Acetate] The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate — Ther Adv Gastroenterol 2016. PMID 26770266
- [Larazotide Acetate] Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis — Nat Commun 2020. PMID 32332732
- [Larazotide Acetate] Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment — J Control Release 2025. PMID 40915363
- [Teduglutide] Teduglutide: A Review in Short Bowel Syndrome — Drugs 2017. PMID 28194723
- [Teduglutide] Teduglutide: a review of its use in the treatment of patients with short bowel syndrome — Drugs 2013. PMID 23729002
- [Teduglutide] Use of Teduglutide in Children With Intestinal Failure: A Systematic Review — Front Nutr 2022. PMID 35774551
FREQUENTLY ASKED
What is the difference between Larazotide Acetate and Teduglutide?
Both act on the intestine but in different ways: larazotide regulates tight junctions to reduce permeability, teduglutide is a GLP-2 analogue approved for short bowel syndrome that increases intestinal absorptive surface.
What is the regulatory status of Larazotide Acetate and Teduglutide?
Larazotide Acetate: Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models. Teduglutide: Approved (EU/US) for short bowel syndrome in adults and children; real-world and paediatric evidence is accumulating.
What safety signals have been reported?
Larazotide Acetate: Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme. Teduglutide: Because it is intestinotrophic, labelling and reviews discuss monitoring for polyp growth; the "double-edged sword" debate centres on this growth effect.
Which studies is this comparison based on?
For Larazotide Acetate: “The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate” (PMID 26770266); “Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis” (PMID 32332732); “Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment” (PMID 40915363). For Teduglutide: “Teduglutide: A Review in Short Bowel Syndrome” (PMID 28194723); “Teduglutide: a review of its use in the treatment of patients with short bowel syndrome” (PMID 23729002); “Use of Teduglutide in Children With Intestinal Failure: A Systematic Review” (PMID 35774551).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use